[go: up one dir, main page]

PE20091035A1 - DERIVATIVES OF 2-AMINOPYRIMIDINE - Google Patents

DERIVATIVES OF 2-AMINOPYRIMIDINE

Info

Publication number
PE20091035A1
PE20091035A1 PE2008001971A PE2008001971A PE20091035A1 PE 20091035 A1 PE20091035 A1 PE 20091035A1 PE 2008001971 A PE2008001971 A PE 2008001971A PE 2008001971 A PE2008001971 A PE 2008001971A PE 20091035 A1 PE20091035 A1 PE 20091035A1
Authority
PE
Peru
Prior art keywords
pyrimidin
amine
atoms
alkyl
aminopyrimidine
Prior art date
Application number
PE2008001971A
Other languages
Spanish (es)
Inventor
Gonzalez Elena Carceller
Fuentes Eva Maria Medina
Via Josep Marti
Bernado Marina Virgili
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of PE20091035A1 publication Critical patent/PE20091035A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-AMINOPIRIMIDINA DE FORMULA (I) DONDE R1 ES ALQUILO(C2-C8) O CICLOALQUILO(C3-C7)-ALQUILO(C0-C4) OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C4), FENILO O FLUOR; R2 Y R3 FORMAN JUNTO EL ATOMO DE N AL CUAL ESTAN UNIDOS UN HETEROCICLICO MONOCICLICO DE 4 A 7 ATOMOS, BICICLICO DE 7 A 8 ATOMOS O BICICLICO FUSIONADO DE 8 A 12 ATOMOS. SON COMPUESTOS PREFERIDOS: 4-(CICLOPROPILMETIL)-6-((3R)-3-(METILAMINO)PIRROLIDIN-1-IL)PIRIMIDIN-2-AMINA, 4-CICLOPROPILMETIL-6-(3-(METILAMINO)AZETIDIN-1-IL)PIRIMIDIN-2-AMINA, 4-CICLOPROPILMETIL-6-((3R)-3-AMINOPIRROLIDIN-1-IL)PIRIMIDIN-2-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE HISTAMINA H4 SIENDO UTILES EN EL TRATAMIENTO DE ASMA, RINITIS ALERGICA, DERMATITIS, PSORIASIS, URTICARIAREFERS TO COMPOUNDS DERIVED FROM 2-AMINOPYRIMIDINE FROM FORMULA (I) WHERE R1 IS ALKYL (C2-C8) OR CYCLALKYL (C3-C7) -ALKYL (C0-C4) OPTIONALLY SUBSTITUTED WITH ALKYL (C1-C4), FENYL ; R2 AND R3 TOGETHER FORM THE ATOM OF N TO WHICH THEY ARE UNITED A MONOCYCLIC HETEROCYCLIC OF 4 TO 7 ATOMS, BICYCLE OF 7 TO 8 ATOMS OR FUSED BICYCLE OF 8 TO 12 ATOMS. PREFERRED COMPOUNDS ARE: 4- (CYCLOPROPylmethyl) -6 - ((3R) -3- (METHYLAMINE) PYRROLIDIN-1-IL) PYRIMIDIN-2-AMINE, 4-CYCLOPROPYLMEthyl-6- (3- (METHYLAMINE) AZETIDIN-1- IL) PYRIMIDIN-2-AMINE, 4-CYCLOPROPYLMETIL-6 - ((3R) -3-AMINOPYRROLIDIN-1-IL) PYRIMIDIN-2-AMINE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR, BEING USEFUL IN THE TREATMENT OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, PSORIASIS, URTICARIA

PE2008001971A 2007-11-30 2008-11-25 DERIVATIVES OF 2-AMINOPYRIMIDINE PE20091035A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07381074 2007-11-30

Publications (1)

Publication Number Publication Date
PE20091035A1 true PE20091035A1 (en) 2009-07-16

Family

ID=39197144

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001971A PE20091035A1 (en) 2007-11-30 2008-11-25 DERIVATIVES OF 2-AMINOPYRIMIDINE

Country Status (5)

Country Link
AR (1) AR069480A1 (en)
CL (1) CL2008003537A1 (en)
PE (1) PE20091035A1 (en)
TW (1) TW200936570A (en)
WO (1) WO2009068512A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008545D1 (en) 2006-03-31 2010-09-30 Janssen Pharmaceutica Nv BENZOIMIDAZOLE-2-YL PYRIDINES AND PYRAZINES AS HISTAMINE H4 RECEPTOR MODULATORS
CN101511190A (en) 2006-07-11 2009-08-19 詹森药业有限公司 Pressure sensor fault detection
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2493895B1 (en) 2009-10-29 2017-04-26 Vectura Limited N-containing heteroaryl derivatives as jak3 kinase inhibitors
US8901146B2 (en) * 2009-12-23 2014-12-02 Medicis Pharmaceutical Corporation Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
BR112014003496B1 (en) 2011-08-18 2022-02-22 Nippon Shinyaku Co., Ltd Heterocyclic derivative, uses thereof and pharmaceutical composition
WO2013182711A1 (en) 2012-06-08 2013-12-12 Sensorion H4 receptor inhibitors for treating tinnitus
WO2014010748A1 (en) * 2012-07-10 2014-01-16 Shionogi & Co., Ltd. Cyclopropane derivative having bace1 inhibiting activity
PL2964229T3 (en) 2013-03-06 2020-05-18 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
WO2017160922A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
WO2017160925A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
GB201817047D0 (en) 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
RU2008114378A (en) * 2005-09-13 2009-10-20 Палау Фарма, С.А. (Es) 2-AMINOPYRIMIDINE DERIVATIVES AS ACTIVITY MODULATORS OF THE H4-HISTAMIN RECEPTOR
NL2000323C2 (en) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
EP2066645A2 (en) * 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor

Also Published As

Publication number Publication date
CL2008003537A1 (en) 2009-03-06
TW200936570A (en) 2009-09-01
WO2009068512A1 (en) 2009-06-04
AR069480A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
PE20091035A1 (en) DERIVATIVES OF 2-AMINOPYRIMIDINE
PE20120321A1 (en) INDAZOLES SUBSTITUTED WITH OXAZOLE AS PI3-KINASE INHIBITORS
PE20110061A1 (en) DIAMINE-PYRIDINE, PYRIMIDINE AND PYRIDAZINE DERIVATIVES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR
EA201100079A1 (en) DERIVATIVES OF TRIAZOLE [4,5-D] PYRAMIDINE AND THEIR APPLICATION AS ANTAGONISTS OF PURIN RECEPTOR
PE20140865A1 (en) BRUTON TYROSINE KINASE INHIBITORS
PE20080186A1 (en) 4,6-DISUSTITUTED DERIVATIVES OF 2-METHOXY-6-ETHYLAMINE-PYRIMIDINE AS ANTAGONISTS OF THE D2-PROSTAGLANDIN RECEPTOR
PE20070407A1 (en) COMPOUNDS DERIVED FROM PIRAZINE AS ANTAGONISTS OF THE ADENOSINE A2B RECEPTOR
PE20090773A1 (en) DERIVATIVES OF MORPHOLINE PYRIMIDINE
PE20091173A1 (en) HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
PE20070848A1 (en) PYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS
PE20160839A1 (en) DERIVATIVES OF 4-AZAINDOL
NO20063599L (en) Further heterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
PE20100138A1 (en) MORPHOLIN PYRIMIDINE DERIVATIVES USED IN MTOR KINASE AND / OR PI3K-RELATED DISEASES
PE20091524A1 (en) DERIVATIVES OF 2-AMINOPYRIMIDINE
PE20090717A1 (en) QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
PE20091734A1 (en) 2-IMINO-3-METHYLPYRROLOPYRIMIDINONE PHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
PE20120031A1 (en) ARYL METHYL BENZOQUINAZOLINONE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR
PE20121050A1 (en) N- (1- (4- (1H-PYRAZOLE-5-IL) FTALAZIN-1-IL) PIPERIDIN-4-IL) -BENZAMIDE COMPOUNDS SUBSTITUTE AS ANTAGONISTS IN THE HEDGEHOG TRAJECTORY
CY1111477T1 (en) SULFUR Pyridines as allosteric enhancers of the M4 muscarinic receptor
PE20110409A1 (en) HETEROCYCLIC ANTIVIRIC COMPOUNDS
PE20090714A1 (en) IMIDAZOPYRIDAZINES AND PYROLO-PYRIMIDINES SUBSTITUTED AS LIPID KINASE INHIBITORS
PE20141685A1 (en) NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS
MX2009010503A (en) Heterocyclic antiviral compounds.
PE20110807A1 (en) KINASE INHIBITORS AKT AND P70 S6

Legal Events

Date Code Title Description
FD Application declared void or lapsed